Every Decision Impacts a Life.

We understand there is a human consequence to every decision that life sciences companies make. With our nearly 30-year history of offering evidence-based solutions and our commitment to a greater purpose, there’s no better partner to successfully see your drug through from molecule to market and beyond.

Featured Intelligence

Live Webinar

Part D in Peril: The Inconvenient Math of IRA Part D Redesign 

Your choice of 3 sessions:
August 14, 2025 | 12:00 – 12:45 PM ET
August 18, 2025 | 12:00 – 12:45 (UTC +8:00) – Asia
August 18, 2025 | 12:00 – 12:45 CET – Europe/Berlin 

Trinity Infinity

STRATEGY

Seasoned life sciences, therapeutic and functional expertise

INSIGHTS

Rigorous market research, real-world data and proprietary benchmarks

ANALYTICS

Cutting edge analytics and digital transformation solutions with clinical & commercial applications

Featured News

LATEST INTELLIGENCE

Briefs

2025 Annual State of Learning & Development in Life Sciences

Through the 2020s, life sciences leaders have dealt with one challenge after another. The shock of the COVID-19 pandemic. Sticky inflation. Return-to-office mandates. The intense pressure to perform in the face of disruptive challenges has proven constant. For commercial learning and development, also known as commercial L&D, this has presented new roadblocks and innovations alike, […]

 Read More

Briefs

Leading the Evolution: Navigating AI and Pharma Market Trends

How are Commercial, Medical and Market Access organizations evolving to develop capabilities and accelerate innovation in 2025 and beyond? Executive leaders are focused on making informed organizational decisions to propel the evolution of capabilities in this rapidly changing global economy. As you strategize to optimize structure, talent and capabilities to excel in the future, this Advisory Brief brings you critical insights gleaned from the recent TGaS Advisors’ 2025 Spring Summit.

 Read More

Webinars

Part D in Peril: The Inconvenient Math of IRA Part D Redesign 

August 14, 2025 | 12:00 – 12:45 PM ET

Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.

 Sign Up Now

Join our team

As a company, we value trust – both within our company and with our customers. Trinity has a track record of unflinching commitment to our endeavors, always going beyond what is expected. We pride ourselves on our shared dedication to advancing the life sciences and on our passion for healthcare.